🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Valeant appoints Tyco's Sam Eldessouky corporate controller

Published 26/05/2016, 16:53
© Reuters. Company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval
PSON
-
PRGO
-

(Reuters) - Valeant Pharmaceuticals International Inc appointed Tyco International Plc executive Sam Eldessouky as corporate controller as the Canadian drugmaker works to rebuild its reputation amid criticism of its accounting methods.

Valeant said in March that "improper conduct" by former Chief Financial Officer Howard Schiller and former Corporate Controller Tanya Carro had contributed to a misstatement of its financial results.

Eldessouky's appointment follows the replacement of Michael Pearson (LON:PSON) as chief executive by Joseph Papa, former CEO of drugmaker Perrigo Co (NYSE:PRGO) Plc, and the resignation of former Executive Vice President Deb Jorn.

Schiller stepped down as CFO in 2015 but stayed on as a member of the board. He will not stand for re-election.

Eldessouky joined Tyco in 2004, two years after senior managers including Chief Executive Dennis Kozlowski were charged with looting more than $150 million from the company. He leaves as controller and chief accounting officer of the security systems maker.

Valeant said Eldessouky would direct accounting and financial reporting activities to ensure accurate and timely compliance with all internal and external requirements. He starts on May 31.

The drugmaker, a former investor favorite, has lost about 60 percent of its value since March 14, the day before it said a delay in the filing of its annual report could put it at risk of a default on its borrowings.

Apart from the company's financial problems, it has faced criticism for its practice of sharply increasing the prices of the drugs acquired through a slew of takeovers.

Valeant said on Tuesday it was reviewing its compensation policies for executives to reflect the current environment.

© Reuters. Company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval

The company's U.S.-listed shares, which traded as high as $263.81 in August, were down 1.7 percent at $26.64 at midday on Thursday. Its Toronto-listed shares were down 1.4 percent at C$34.55.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.